Kiniksa Pharmaceuticals International Plc (KNSA)
95.76
+0.74
(+0.78%)
USD |
NASDAQ |
Nov 11, 16:00
95.83
+0.07
(+0.07%)
After-Hours: 20:00
Kiniksa Pharmaceuticals International Enterprise Value : 6.955B for Nov. 11, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 11, 2026 | 6.955B |
| November 10, 2026 | 6.897B |
| November 09, 2026 | 7.190B |
| November 06, 2026 | 6.806B |
| November 05, 2026 | 6.372B |
| November 04, 2026 | 6.983B |
| November 03, 2026 | 6.761B |
| November 02, 2026 | 6.565B |
| October 30, 2026 | 6.678B |
| October 29, 2026 | 7.096B |
| October 28, 2026 | 6.909B |
| October 27, 2026 | 6.440B |
| October 26, 2026 | 5.167B |
| October 23, 2026 | 5.461B |
| October 22, 2026 | 5.780B |
| October 21, 2026 | 5.694B |
| October 20, 2026 | 5.967B |
| October 19, 2026 | 5.677B |
| October 16, 2026 | 5.607B |
| October 15, 2026 | 5.713B |
| October 14, 2026 | 5.627B |
| October 13, 2026 | 5.602B |
| October 12, 2026 | 5.658B |
| October 09, 2026 | 5.701B |
| October 08, 2026 | 5.620B |
| Date | Value |
|---|---|
| October 07, 2026 | 5.558B |
| October 06, 2026 | 5.489B |
| October 05, 2026 | 5.428B |
| October 02, 2026 | 5.387B |
| October 01, 2026 | 5.343B |
| September 30, 2026 | 5.295B |
| September 29, 2026 | 5.388B |
| September 28, 2026 | 5.417B |
| September 25, 2026 | 5.338B |
| September 24, 2026 | 5.358B |
| September 23, 2026 | 5.416B |
| September 22, 2026 | 5.565B |
| September 21, 2026 | 5.576B |
| September 18, 2026 | 5.506B |
| September 17, 2026 | 5.669B |
| September 16, 2026 | 5.536B |
| September 15, 2026 | 5.343B |
| September 14, 2026 | 5.455B |
| September 11, 2026 | 5.430B |
| September 10, 2026 | 5.447B |
| September 09, 2026 | 5.606B |
| September 08, 2026 | 5.494B |
| September 04, 2026 | 5.558B |
| September 03, 2026 | 5.758B |
| September 02, 2026 | 5.713B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Autolus Therapeutics Plc | 520.23M |
| Scancell Holdings Plc | -- |
| OptiBiotix Health Plc | -- |
| Adaptimmune Therapeutics Plc | -- |
| Bicycle Therapeutics Plc | -268.71M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 47.34M |
| Revenue (Quarterly) | 285.97M |
| Total Expenses (Quarterly) | 238.62M |
| EPS Diluted (Quarterly) | 0.5575 |
| Gross Profit Margin (Quarterly) | 53.22% |
| Profit Margin (Quarterly) | 16.56% |
| Earnings Yield | 1.37% |
| Operating Earnings Yield | 1.64% |
| Normalized Earnings Yield | 1.369 |